Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael W. Miller(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sue‐Ing Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gautam Agnihotri(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ravi P. Nargund(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert E. Drolet(United States Military Academy), Marco A. S. Baptista(Merck & Co., Inc., Rahway, NJ, USA (United States)), Duane E. DeMong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarah W. Li, Mark W. Embrey(United States Military Academy), Ronald K. Chang(United States Military Academy), Eric M. Parker(University of New Hampshire), Marc Poirier(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alan Hruza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Walsh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhicai Shi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Sanders(United States Military Academy), Megan K. Macala(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark T. Bilodeau(Kettering University), Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sylvie M. Sur(United States Military Academy), Christian Mirescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Morrow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan Kern(LIGO Scientific Collaboration), Zhizhang Yin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Heather E. Tiscia(United States Military Academy), Joel M. Harris(University of Utah), John J. Renger(United States Military Academy), Matthew Fell(Swansea Bay University Health Board), Thomas J. Greshock(University of Michigan), Kallol Basu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoping Zhang(Tongji University), Hong Liu(North West Agriculture and Forestry University), Xiaoping Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Li Xiao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yinghui Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xing Dai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hong Mei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Honglu Zhang(QB3), John Columbus(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. McCauley(Fox Chase Cancer Center), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhiyong Hu(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 147
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents
|Proceedings of the National Academy of Sciences|1999|326